Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Importantly, 6 of the 8 combination-treated tg mice showed <0.1% residual tumor cells ( Figure 4 E), resulting in increased minimal residual disease–low survival in group 6 vs other groups, with a trend that did not reach statistical significance ( Figure 4 F).

also in 111,027 other papers